Juniper and Turk Telekom Join Forces to Create Open RAN 5G Ecosystem
shot by IP News Shots / 6:32 pm on 20 January, 2021
A technology and commercial partnership has been established between Juniper Networks Inc. and the Turk Telekom Group for the development of an Open RAN 5G ecosystem. The partnership will include an exclusive global licensing deal with a subsidiary of Turk Telekom, Netsia to give access to its Radio Intelligent Controller (RIC) technology including related source code and patents.
Read More at: https://datacentrenews.eu/story/juniper-networks-and-turk-telekom-group-work-to-develop-open-ran-5g-ecosystem
Industry: Telecommunications
Mogrify to Gain Access to IP Developed During Exploratory Research Project with MRC LMB
shot by IP News Shots / 6:29 pm on 12 January, 2021
Mogrify Limited and MRC Laboratory of Molecular Biology have entered into exploratory research collaboration for the development of new protein expression systems by using recent innovations in direct cell reprogramming. Any intellectual property (IP) as well as know-how developed during the collaboration will be accessed by Mogrify for commercialization of technology in therapeutic applications.
Read More at: https://www.contractpharma.com/contents/view_breaking-news/2021-01-11/mogrify-enters-research-collaboration-with-mrc-lmb/
Industry: Biotechnology
Merger of Three Medtech Companies On the Cards
shot by IP News Shots / 8:39 pm on 06 January, 2021
Avingtrans Plc, a majority stakeholder in Scientific Magnetics will be acquiring a majority of shares in a merger involving Scientific Magnetics, its subsidiary Tecmag Inc. and Magnetica Pty Ltd. The merger that will result in a company by the name Magnetica, will be strengthened with a comprehensive product portfolio and will also get access to the core intellectual property of Scientific Magnetics and Tecmag.
Read More at: https://www.medicaldesignandoutsourcing.com/3-medtech-engineering-businesses-plan-to-merge/
Industry: Healthcare Technology
Lantern to Join Forces with Califia for Launching Antibody Drug Conjugate Program
shot by IP News Shots / 6:23 pm on 05 January, 2021
Lantern Pharma, Inc. and Califia Bio, Inc. are set to work on the launch of an Antibody Drug Conjugate (ADC) program through an evaluation and potential development agreement. “Notably, Lantern will possibly leverage the patented linker library, conjugation processes and payloads, etc., for development as ADC-based therapies. “Additionally, Lantern will make use of its AI platform RADR to identify the cancer types, targets, and biomarker signatures that are anticipated to respond to and benefit from ADC approach.
Industry: Pharmaceuticals
SpiceJet to Use PLUSS’ Celsure for COVID-19 Vaccine Delivery
shot by IP News Shots / 6:04 pm on 31 December, 2020
SpiceJet Limited has signed a Memorandum of Understanding (MoU) with Pluss Advanced Technologies (PLUSS) to receive a supply of their patent-protected product ‘Celsure’. The product will be used in the last mile delivery of the highly-sensitive COVID-19 vaccines which require extremely precise transportation and storage conditions to retain effectiveness.
Read More at: https://www.itln.in/spicejet-signs-mou-with-pluss-for-covid-vaccine-delivery-aviation
Industry: Healthcare Equipment & Supplies
Pluristem and Innovare Join Hands to Expand Clinical Program of PLX Cells in ARDS Treatment
shot by IP News Shots / 6:20 pm on 30 December, 2020
Pluristem Therapeutics Inc. and Innovare R&D have signed a collaboration agreement to expand the former’s clinical program for use of PLX cells in the treatment of Acute Respiratory Distress Syndrome (ARDS) related to COVID-19. Innovare will be responsible for the logistics as well as the clinical trials. It will also fund the study which will be carried out with the PLX cells purchased from Pluristem. As per the agreement, Innovare will get exclusive distribution rights for the supply of PLX cells in the treatment of COVID-19, subject to positive trial results and regulatory approvals. The intellectual property and manufacturing rights will remain with Pluristem.
Industry: Pharmaceuticals